{"id":3825,"date":"2023-06-13T21:10:10","date_gmt":"2023-06-14T02:10:10","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=3825"},"modified":"2023-06-13T21:11:04","modified_gmt":"2023-06-14T02:11:04","slug":"vaccine-candidate-for-chikungunya-virus-safe-and-effective","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2023\/06\/13\/vaccine-candidate-for-chikungunya-virus-safe-and-effective\/","title":{"rendered":"Vaccine Candidate for Chikungunya Virus Safe and Effective"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/www.medpagetoday.com\/infectiousdisease\/vaccines\/104984?xid=nl_mpt_DHE_2023-06-13&amp;eun=g1462072d0r&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Daily%20Headlines%20Evening%202023-06-13&amp;utm_term=NL_Daily_DHE_dual-gmail-definition\">MedPageToday<\/a> <\/p>\n\n\n\n<p>A single dose of the live-attenuated vaccine candidate VLA1553 for the prevention of disease caused by chikungunya virus produced a strong immune response, a phase III randomized trial showed.<\/p>\n\n\n\n<p>At 28 days post-vaccine, 98.9% of participants in the per-protocol population who received the vaccine had seroprotective chikungunya virus neutralizing antibody levels (95% CI 96.7-99.8,\u00a0<em>P<\/em>&lt;0.0001), independent of age, reported Martina Schneider, PhD, the clinical strategy manager at Valneva in Vienna, the company that produces the vaccine, and colleagues.<\/p>\n\n\n\n<p>Adverse events were similar to other licensed vaccines, and VLA1553 was well tolerated by both younger and older adults, they noted in\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(23)00641-4\/fulltext\" target=\"_blank\"><em>The Lancet<\/em><\/a><\/p>\n\n\n\n<p>&#8220;This could be the first chikungunya vaccine available for people living in endemic regions, as well as for travelers to endemic areas or areas at risk for an upcoming outbreak,&#8221; Schneider said in a press release. &#8220;Our promising results showed good persistence of antibody levels after vaccination, which is important considering that chikungunya outbreaks may recur suddenly.&#8221;<\/p>\n\n\n\n<p>No significant difference was seen in the seroprotection rate between patients ages 18 to 64 (98.6%) and those 65 and older (100%). At 180 days, 96.3% of those in the VLA1553 arm still had titers above the seroprotective level of antibodies.<\/p>\n\n\n\n<p>&#8220;As age is a risk factor for severity and mortality of chikungunya disease, the strong immune response observed in older participants might be particularly beneficial,&#8221; Schneider said.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.medpagetoday.com\/infectiousdisease\/vaccines\/104984?xid=nl_mpt_DHE_2023-06-13&amp;eun=g1462072d0r&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Daily%20Headlines%20Evening%202023-06-13&amp;utm_term=NL_Daily_DHE_dual-gmail-definition\">Continue reading<\/a><\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>MedPageToday A single dose of the live-attenuated vaccine candidate VLA1553 for the prevention of disease caused by chikungunya virus produced a strong immune response, a phase III randomized trial showed. At 28 days post-vaccine, 98.9% of participants in the per-protocol population who received the vaccine had seroprotective chikungunya virus neutralizing antibody levels (95% CI 96.7-99.8,\u00a0P&lt;0.0001), [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[8],"tags":[],"class_list":["post-3825","post","type-post","status-publish","format-standard","hentry","category-vaccine-headlines"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=3825"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3825\/revisions"}],"predecessor-version":[{"id":3826,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3825\/revisions\/3826"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=3825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=3825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=3825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}